Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
Carcinoma, Renal Cell · Advanced Renal Cell Carcinoma · Renal Cancer · Renal Neoplasm · Clear Cell Renal Cell Carcinoma · Metastatic Renal Cell Carcinoma · Clear-cell Metastatic Renal Cell Carcinoma · Carcinoma, Renal Cell Metastasis · Advanced or Metastatic Renal Cell Carcinoma · Carcinoma, Renal Cell, Advanced · Metastatic Renal Cell Cancer · Metastatic Renal Cell Carcinoma ( mRCC) · Metastatic/Advanced Renal Cell Carcinoma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 224 (planned)
- Started
- Feb 10, 2026
- Main results expected
- Nov 2, 2027
- Fully finished
- Nov 1, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Confirmed objective response rate (ORR) using RECIST v1.1 as assessed by investigator
Measured over: Up to approximately 3 years
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Measured over: Through 90 days after the last study intervention (Up to approximately 3 years)
Number of participants with dose limiting toxicity (DLT)
Measured over: Though end of DLT evaluation period (Up to approximately 3 years)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07227415 · record last updated 2026-10-08 · checked 2026-11-09 15:36 UTC